Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant meningioma with aggressive clinical course. It recurs in approximately 50-78% of the cases. This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.
Biomarker and diagnostic research for grade III meningioma has been reported in the published literature.
8 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 6 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04659811](https://clinicaltrials.gov/study/NCT04659811) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 8:11 PM UTC
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma |
PHASE2 |
Nancy Ann Oberheim Bush, MD |
ACTIVE_NOT_RECRUITING |
[NCT07428616](https://clinicaltrials.gov/study/NCT07428616) | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | PHASE2 | Exelixis | RECRUITING |
[NCT04082520](https://clinicaltrials.gov/study/NCT04082520) | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | PHASE2 | Mayo Clinic | RECRUITING |
[NCT03604978](https://clinicaltrials.gov/study/NCT03604978) | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | PHASE1 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT02847559](https://clinicaltrials.gov/study/NCT02847559) | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | PHASE2 | Northwestern University | UNKNOWN |
20 publications have been identified in PubMed for grade III meningioma. Research spans Review / Meta-Analysis (20%), Case Report / Case Series (20%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 | 20% |
Patient case studies | 4 | 20% |
Laboratory research | 4 | 20% |
Disease patterns and progression | 4 | 20% |
Testing and diagnosis research | 2 | 10% |
Clinical study results | 2 | 10% |
Gao M (2026). [PMID: 42103619](https://pubmed.ncbi.nlm.nih.gov/42103619/). *Zhonghua Bing Li Xue Za Zhi*. [Basic Science / Preclinical]
Jiang S (2026). [PMID: 42135724](https://pubmed.ncbi.nlm.nih.gov/42135724/). *J Transl Med*. [Basic Science / Preclinical]
Vu KV (2026). [PMID: 41730635](https://pubmed.ncbi.nlm.nih.gov/41730635/). *AJNR Am J Neuroradiol*. [Diagnostic / Biomarker]
Li X (2026). [PMID: 41522606](https://pubmed.ncbi.nlm.nih.gov/41522606/). *Research (Wash D C)*. [Review / Meta-Analysis]
Ehret F (2026). [PMID: 42149137](https://pubmed.ncbi.nlm.nih.gov/42149137/). *Clin Cancer Res*. [Clinical Trial Publication]
Xu R (2025). [PMID: 41613327](https://pubmed.ncbi.nlm.nih.gov/41613327/). *Front Med (Lausanne)*. [Case Report / Case Series]
Szőke P (2025). [PMID: 40718644](https://pubmed.ncbi.nlm.nih.gov/40718644/). *Neurooncol Adv*. [Basic Science / Preclinical]
Dalal M (2025). [PMID: 41437098](https://pubmed.ncbi.nlm.nih.gov/41437098/). *J Transl Med*. [Basic Science / Preclinical]
Bosio A (2025). [PMID: 40759981](https://pubmed.ncbi.nlm.nih.gov/40759981/). *Trials*. [Clinical Trial Publication]
Rallapalli R (2025). [PMID: 41328297](https://pubmed.ncbi.nlm.nih.gov/41328297/). *Rare Tumors*. [Case Report / Case Series]